William Audeh, MD

Articles by William Audeh, MD

26 Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies

ByWilliam Audeh, MD,Harshini Ramaswamy,Andrea Menicucci

July 27th 2024

33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

ByWilliam Audeh, MD,Nicole Chmielewski-Stivers,Harshini Ramaswamy,Andrea Menicucci

June 30th 2024

Managed Care: The View From Salick Managed Care

ByWilliam Lew Quan, PharmD,William Audeh, MD

February 1st 1996

In the past few years, this country has seen a major change in the financing of health care. According to a recent survey by Foster Higgins, an international employee-benefits consulting agency, at the end of 1994, 63% of all privately insured Americans were enrolled in a managed care plan.

Latest Updated Articles

Managed Care: The View From Salick Managed Care
February 1st 1996

William Audeh, MD

Articles by William Audeh, MD

26 Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies

33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

Managed Care: The View From Salick Managed Care

Latest Updated Articles

Trending on CancerNetwork

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC

IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma

SOHO 2026: Key Updates Across the Multiple Myeloma Continuum

PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data

Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy